305 related articles for article (PubMed ID: 27741368)
1. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
4. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
[TBL] [Abstract][Full Text] [Related]
5. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
6. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
[TBL] [Abstract][Full Text] [Related]
7. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
8. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.
Castellarin M; Milne K; Zeng T; Tse K; Mayo M; Zhao Y; Webb JR; Watson PH; Nelson BH; Holt RA
J Pathol; 2013 Mar; 229(4):515-24. PubMed ID: 22996961
[TBL] [Abstract][Full Text] [Related]
9. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
10. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
11. Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.
Kim TM; Jung SH; Baek IP; Lee SH; Choi YJ; Lee JY; Chung YJ; Lee SH
J Pathol; 2014 Aug; 233(4):425-35. PubMed ID: 24870262
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
[TBL] [Abstract][Full Text] [Related]
13. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed AA; Etemadmoghadam D; Temple J; Lynch AG; Riad M; Sharma R; Stewart C; Fereday S; Caldas C; Defazio A; Bowtell D; Brenton JD
J Pathol; 2010 May; 221(1):49-56. PubMed ID: 20229506
[TBL] [Abstract][Full Text] [Related]
14. Low-grade serous carcinomas of the ovary contain very few point mutations.
Jones S; Wang TL; Kurman RJ; Nakayama K; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Shih IeM
J Pathol; 2012 Feb; 226(3):413-20. PubMed ID: 22102435
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
16. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.
Lin S; Wang C; Zarei S; Bell DA; Kerr SE; Runger GC; Kocher JA
BMC Genomics; 2018 Nov; 19(1):841. PubMed ID: 30482155
[TBL] [Abstract][Full Text] [Related]
17. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN
PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043
[TBL] [Abstract][Full Text] [Related]
18. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
19. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.
Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG
Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721
[TBL] [Abstract][Full Text] [Related]
20. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
